Spyryx Biosciences Company
Spyryx Biosciences develops a next-generation therapeutics for obstructive lung diseases.
Total Funding:
$18.2M
Investor Type:
For Profit
Technology:
Biologics
Last Funding Type:
Series A
Estimated Revenue:
$1M to $10M
Founded Date:
2013
Industry:
PharmTech
Employee Number:
11-50
Funding Status:
Early Stage Venture
Headquarters:
Durham, North Carolina, United States
Investors Number:
3